Celgene To Pay $280M To End Off-Label Cancer Drug FCA Suit

Law360, Los Angeles (July 25, 2017, 6:12 PM EDT) -- Celgene Corp. has agreed to shell out $280 million to end a False Claims Act suit launched in California by a whistleblower who accused the drug company of promoting off-label uses for two cancer drugs, federal prosecutors announced on Tuesday.

The long-running case was filed by former sales rep Beverly Brown, who said the company promoted two bone cancer drugs — Thalomid and Revlimid —for other cancers they weren’t approved to treat, and paid physicians kickbacks to promote the drugs’ expanded use. In addition to False Claims Act violations, the suit also alleged Celgene violated the laws of 28 states and...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!